Filing Flows

Filing Flows › Inovio Pharmaceuticals (INO) › Who owns the stock

Who owns Inovio Pharmaceuticals (INO) stock

98 funds reported Inovio Pharmaceuticals (INO) shares in their latest 13F filings, worth $47.7M in all. The largest holder is FMR LLC ($9.3M). Last quarter 41 funds added to their stakes and 30 cut them.

Largest holders of INO (13F)Largest holders of INO (13F)FMR LLC$9.3MJanus Henderson Group$5.8MVanguard Group$5.8MJupiter Topco LLC$5.7MVanguard Capital Management LLC$4.0MBoxer Capital Management, LLC$3.1MADAR1 Capital Management, LLC$2.4MD. E. Shaw$1.5MTwo Sigma Investments, LP$1.4MEversept Partners, LP$1.1M

Largest holders (13F)

FundSharesValueChangeQuarter
FMR LLC8,454,797$9.3Mdecrease2026-06-30
Janus Henderson Group3,308,406$5.8Munchanged2026-03-31
Vanguard Group3,315,580$5.8Mincrease2025-12-31
Jupiter Topco LLC5,171,053$5.7Mbase2026-06-30
Vanguard Capital Management LLC3,650,562$4.0Mincrease2026-06-30
Boxer Capital Management, LLC2,844,994$3.1Mincrease2026-06-30
ADAR1 Capital Management, LLC2,143,910$2.4Mincrease2026-06-30
D. E. Shaw1,351,656$1.5Mdecrease2026-06-30
Two Sigma Investments, LP1,239,778$1.4Mincrease2026-06-30
Eversept Partners, LP1,035,360$1.1Munchanged2026-06-30
Geode Capital Management, LLC802,751$884Kincrease2026-06-30
Millennium Management LLC796,107$876Kdecrease2026-06-30
BlackRock779,057$857Kincrease2026-06-30
Vanguard Fiduciary Trust480,769$529Kincrease2026-06-30
Caption Management, LLC478,950$527Knew2026-06-30

Inovio Pharmaceuticals' latest quarter

Inovio Pharmaceuticals, Q1 2025: revenue $65K, net loss $19.7M, operating cash flow −$26.9M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most INO stock?

By the latest 13F filings: FMR LLC ($9.3M); Janus Henderson Group ($5.8M); Vanguard Group ($5.8M); Jupiter Topco LLC ($5.7M); Vanguard Capital Management LLC ($4.0M).

What is the short interest in INO?

21,304,238 shares were sold short at the 2026-10-15 settlement, 2.34% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.